Eli Lilly & Co. 10-Q Summary: Quarter Ended September 30, 2001
Business Context and Reporting Period
This Form 10-Q covers the quarterly and nine-month periods ended September 30, 2001, for Eli Lilly and Company, a global pharmaceutical firm. The company operates primarily in pharmaceutical products for humans, with a non-material animal health segment. The reporting period was significantly impacted by the entry of generic fluoxetine (Prozac) into the U.S. market in August 2001, following a court ruling invalidating a key patent.
Key Financial Metrics
| Metric | Q3 2001 | Q3 2000 | 9M 2001 | 9M 2000 |
|---|---|---|---|---|
| Net Sales | $2,874.4M | $2,811.9M | $8,713.6M | $7,884.5M |
| Net Income | $570.1M | $778.8M | $2,204.6M | $2,290.5M |
| Diluted EPS | $0.52 | $0.71 | $2.02 | $2.09 |
| Gross Margin | 80.9% | 82.6% | 81.7% | 81.1% |
| Operating Cash Flow (9M) | $2,581.0M (2001) vs $2,651.6M (2000) | |||
| Total Debt | $3.59B (Sep 30, 2001) vs $2.82B (Dec 31, 2000) | |||
| Cash & Equivalents | $2.65B (Sep 30, 2001) vs $4.11B (Dec 31, 2000) |
Material Changes vs. Prior Period
- Revenue Growth Slowdown: Q3 sales grew only 2% year-over-year, a significant deceleration driven by a 38% drop in U.S. Prozac sales due to generic competition. Excluding Prozac, worldwide sales grew 15%.
- Profit Decline: Q3 net income fell 27% to $570.1M. This was driven by lower gross margins and increased operating expenses, alongside specific charges.
- Unusual Charges: The company recorded $90.5M for acquired in-process technology (collaborations with Isis and Bioprojet) and $121.4M in asset impairments and site charges related to manufacturing capacity reviews. An extraordinary charge of $16.6M (net of tax) was recognized for debt repurchases.
- Product Performance: Strong growth was seen in Zyprexa (+26% Q3), Gemzar (+21% Q3), Evista (+29% Q3), and Diabetes care products (+18% Q3), partially offsetting declines in Prozac and anti-infectives.
- Liquidity: Cash and cash equivalents decreased by $1.47B over the nine-month period, primarily due to significant investment purchases ($2.74B), share repurchases ($421.5M), and dividends ($905.4M).
Guidance, Outlook, and Risks
- Financial Expectations: Management expects single-digit sales growth for 2001 and 2002. Excluding unusual items, EPS is projected at $0.59–$0.61 for Q4 2001, $2.75–$2.77 for full-year 2001, and $2.70–$2.80 for 2002.
- Upcoming Charges: A one-time charge of approximately $100M is expected in Q4 2001 for acquired in-process technology related to resiquimod (genital herpes treatment).
- Prozac Litigation: The company filed a petition with the U.S. Supreme Court to review the invalidation of its Prozac patent. While the company expects to prevail, generic competition has already caused a steep sales decline.
- Zyprexa Litigation: The company is defending its Zyprexa patents against challenges from Zenith Goldline and Dr. Reddy's Laboratories. An unfavorable outcome could materially impact operations.
- Regulatory Matters: The FDA issued a "complete response" letter for Xigris (sepsis treatment) and an "approvable" letter for Forteo (osteoporosis), contingent on labeling and manufacturing inspections. The company is also addressing cGMP compliance issues following FDA warning letters.
Key Facts for Investor Verification
- Verify the trajectory of Prozac sales decline and the potential impact of the Supreme Court petition on future revenue.
- Monitor the outcome of Zyprexa patent litigation, given the product's significant contribution to sales growth.
- Assess the impact of the $100M Q4 charge for resiquimod on full-year earnings guidance.
- Review the status of FDA inspections for Xigris and Forteo, as approval delays could affect future product launches.
- Track the company's ability to maintain gross margins as lower-margin products decline and higher-margin products face generic competition.